News Release

PSA screening and 15-year prostate cancer mortality

JAMA

Peer-Reviewed Publication

JAMA Network

About The Study: A single invitation for prostate-specific antigen (PSA) screening compared with standard practice without routine screening reduced prostate cancer deaths at a median follow-up of 15 years in this secondary analysis of a randomized clinical trial. However, the absolute reduction in deaths was small. 

Authors: Richard M. Martin, B.M., B.S., Ph.D., of the University of Bristol in Bristol, United Kingdom, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2024.4011)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being released to coincide with presentation at the 39th Annual European Association of Urology Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.4011?guestAccessKey=4f006acb-c40d-46ea-83d9-38c1f5b3815d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=040624


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.